The Lipoxygenase Inhibitor 2-Phenylmethyl-1-Naphthol (DuP 654) Is a 12(S)-Hydroxyeicosatetraenoic Acid Receptor Antagonist in the Human Epidermal Cell Line SCL-II

Article

Author: Armah, Benjamin ; Raap, Achim ; Kemeny, Lajos ; Arenberger, Petr ; Ruzicka, Thomas

The lipoxygenase inhibitor 2-phenylmethyl-1 -naphthol (DuP 654) has been shown to be an active anti-inflammatory drug in a murine skin inflammation model. Since 12-HETE is as-sumed to have a pathophysiological role in inflammatory skin diseases, and epidermal cells possess high affinity binding sites for 12(S)-HETE, we studied the effect of DuP 654 on 12(S)-HETE binding to the human epidermal cell line SCL-II. DuP 654 antagonized 12(S)-HETE binding in a dose-dependent manner with a Ki of 3.41 ± 0.23 nM. The antagonistic effect was reversible. After 1- and 24-hour preincubation, the drug had no more significant inhibitory effect at concentrations between 10-10 and 10-5M on specific 12(S)-HETE binding (Bmax of 215,000 ± 21,000 receptors per cell) or on receptor affinity (Kd of 3.25 ± 0.42 nM). Our results show that DuP 654, in addition to its 5-lipoxygenase inhibitory activity, exhibits 12-HETE receptor antagonist effect, and therefore may be of benefit in skin diseases with elevated 12-HETE levels.

01 Jul 1992·Research communications in chemical pathology and pharmacology

An evaluation of 2-benzyl-1-naphthol (DuP 654) analogs as systemic anti-inflammatory agents.

Article

Author: Pinto, D J ; Kerr, J S ; Stampfli, H F ; Batt, D G

DuP 654 (2-benzyl-1-naphthol) is a topically active anti-inflammatory agent that was evaluated in phase II clinical trials as an anti-psoriatic agent. The compound is a potent 5-lipoxygenase inhibitor and exhibits inhibitory activity against lipopolysaccharide-stimulated release of interleukin-1 from human monocytes. DuP 654 cannot be used as a systemic anti-inflammatory compound due to its rapid and extensive metabolism. Fifteen analogs were synthesized in an attempt to block the systemic route(s) of metabolism. The compounds were evaluated (IP and PO) in the rat carrageenan paw edema inflammation model with plasma samples taken at 1, 2, 3, and 4 hours post-dose. Substitutions at the 4- and/or 8-positions on the naphthol, and/or on the benzyl group of the DuP 654 molecule were unsuccessful in achieving an analog which displayed both oral activity in the inflammatory model and high plasma levels without manifesting toxicity. The low plasma levels of some analogs may indicate poor absorption, high volume of distribution, or that the substitution did not inhibit the high hepatic "first-pass" metabolism observed with DuP 654. Other compounds not studied but similar in structure to DuP 654 may exhibit rapid and extensive metabolism.

01 Jan 1990·Skin Pharmacology and Physiology

Cellular and Biochemical Characterization of the Anti-Inflammatory Effects of DuP 654 in the Arachidonic Acid Murine Skin Inflammation Model (Part 1 of 2)

Article

Author: Ackerman, N R ; Rakich, S M ; Mackin, W M ; Collins, R J ; Bruin, E M ; Batt, D G ; Harris, R R

The possible utility of DuP 654, a potent 5-lipoxygenase inhibitor, for treating human inflammatory skin disease was investigated in murine skin treated with 1.0 mg arachidonic acid (AA). When DuP 654 was applied to murine skin treated with AA, it inhibited the resulting inflammation and influx of cells. High performance liquid chromatography and radioimmunoassay analysis of lipid extracts from AA-treated ears indicated that the influx of polymorphonuclear leukocytes (PMN) was temporally preceded by an appearance of significant amounts of 5-HETE (6.7 ± 1.4 ng/ear) and Leukotriene B4 LTB4 0.92 ± 0.2 ng/ear) when compared with extracts of untreated ears (5-HETE, 02 ± 0.3 ng/ear; LTB4, < 0.1 ng/ear). The levels of the 5-lipoxygenase products were reduced by treatment with 10 µg/ear DuP 654. Lipid extracts from AA-treated ears contain chemotactic activity for human PMN and this chemotactic activity in the AA-treated ears could be reduced but not eliminated by immunosorption with anti-LTB4 antibodies coupled to protein A-agarose. The appearance of the chemotactic activity was inhibited by DuP 654. Taken together, these data suggest that DuP 654 may have utility in human inflammatory skin disease.

100 Deals associated with DuP-654

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 2	US	-	-
Psoriasis	Phase 2	-	Bristol Myers Squibb Co.	-
Psoriasis	Phase 2	US	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

DuP-654

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation